1. Pink Sheet

Another Low Blow For Raising HDL; Merck’s Tredaptive Fails Phase III Trial

With Tredaptive’s failure to meet the primary endpoint in the HPS2-THRIVE study, Merck announces it does not plan to seek regulatory approval of the niacin/laropiprant combination pill in the U.S.

In a terse, single-paragraph statement, Merck & Co. Inc. announced Dec. 20 that its HDL-raising cardiovascular drug Tredaptive (extended-release niacin/laropiprant) failed to meet the primary endpoint in a huge Phase III trial, HPS2-THRIVE, and that the New Jersey pharma no longer plans to seek FDA approval of the drug.

Wall Street was barely phased by the news, just the latest in a series of setbacks for cholesterol therapies based...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Woodcock: Do Not Do The Wrong Study, Even If Against US FDA Advice

 
• By Sarah Karlin-Smith

The former CDER director said she tells sponsors not to conduct an FDA-recommended study design or randomized trial if it will not work.

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By Sue Sutter

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.